Search RIGL
RIGEL PHARMACEUTICALS INC
Nasdaq · CIK 1034842
Last close47.15
Daily change+0.18 (0.38%)
10 Years gain+19.07%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
RIGL · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
76.4Momentum
100.0Acceleration
100.0Confidence
77.0Annual Revenue10
Quarterly Revenue38
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.6 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.6129 percentage points.
Operating leverageOperating margin improved by 28.8864 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 7.7109%.
Key Metrics
Revenue Growth TTM76.37%OK
Revenue CAGR 3Y34.76%OK
Gross Margin92.75%OK
Operating Margin40.49%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC60.89%OK
Incremental Operating Margin 3Y107.56%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y7.71%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $294.28M | $274.66M | $125.47M | $75.66M | n/a | 93.33% | 42.63% | n/a | 59.31% | 18.84M |
| 2025 FY Dec 31, 2024 | $179.28M | $160.63M | $24.19M | $31.47M | n/a | 89.6% | 13.49% | n/a | n/a | 17.69M |
| 2025 FY Dec 31, 2023 | $116.88M | $109.77M | -$20.49M | -$5.74M | n/a | 93.92% | -17.53% | n/a | n/a | 17.4M |
| 2024 FY Dec 31, 2022 | $120.24M | $118.49M | -$55.55M | -$73.76M | n/a | 98.55% | -46.2% | n/a | n/a | 17.05M |
| 2023 FY Dec 31, 2021 | $149.24M | $148.15M | -$12.50M | $5.88M | $5.25M | 99.27% | -8.37% | 3.52% | n/a | 170.49M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $308.67M | sum latest 4 fiscal quarters Revenue | OK | 0001034842-26-000052, 0001104659-25-106268 |
| Revenue Growth TTM | 76.37% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001034842-26-000052, 0001104659-25-106268 |
| Revenue CAGR 3Y | 34.76% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001034842-26-000015 |
| Revenue CAGR 5Y | 22.06% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001034842-26-000015 |
| Gross Profit CAGR 3Y | 32.34% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001034842-26-000015 |
| Operating Income Growth | 515.38% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001034842-26-000052, 0001104659-25-106268 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 92.75% | Gross Profit / Revenue | OK | 0001034842-26-000052, 0001104659-25-106268 |
| Operating Margin | 40.49% | Operating Income / Revenue | OK | 0001034842-26-000052, 0001104659-25-106268 |
| ROIC | 60.89% | NOPAT / Average Invested Capital | OK | 0001034842-26-000052, 0001104659-25-106268 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001034842-26-000052 |
| Current Ratio | 1.94x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $15.77 | Revenue / Diluted Shares | OK | 0001034842-26-000052, 0001104659-25-106268 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |